Patients with low-risk cutaneous squamous cell carcinoma do not require extended out-patient follow-up

Cutaneous squamous cell carcinoma (cSCC) are amongst the most common cancers with metastatic potential. Specific clinical and pathological "high-risk" features are used to determine the risk of loco-regional recurrence1-4. Current national guidelines recommend that patients with "high-risk" disease receive specialist follow-up for 2-3 years1. Whilst guidance on what constitutes "high-risk" disease appears consistent and evidence-based1, guidance on what constitutes "low-risk" disease is comparatively vague (despite good evidence suggesting minimal risk in the absence of "high-risk" factors2), which could result in unnecessary follow-up regimens that are more reflective of local preferences.

http://ift.tt/2oGimLr